黃亮，準(zhǔn)聘副教授，主任醫(yī)師，博士研究生導(dǎo)師。任中國醫(yī)學(xué)科學(xué)院血液病醫(yī)院臨床研究平臺負(fù)責(zé)人、病區(qū)主任、PI。獲科技部重點研發(fā)專項課題、“863計劃”青年科學(xué)家專題、國家自然科學(xué)基金面上項目、中國醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與健康科技創(chuàng)新工程項目等資助。曾入選首期“楚天英才·湖北省青年拔尖人才計劃”。 院校引進人才，2024年加入院校。曾在華中科技大學(xué)同濟醫(yī)學(xué)院附屬同濟醫(yī)院任副教授、主任醫(yī)師，并擔(dān)任血液內(nèi)科副主任等職務(wù)。

長期從事淋巴系統(tǒng)腫瘤的精準(zhǔn)診療和臨床轉(zhuǎn)化研究，包括：1. 系統(tǒng)解析免疫治療中免疫效應(yīng)和炎癥反應(yīng)的影響因素與機制，旨在突破免疫治療失敗與不良反應(yīng)兩大臨床瓶頸；2. 侵襲性淋巴瘤、EBV相關(guān)淋巴增殖性疾病的發(fā)病機制與精準(zhǔn)診療；3. 免疫、基因編輯等個性化創(chuàng)新療法的臨床轉(zhuǎn)化研究。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

(1) Cheng J^#, Hu X^#, Dai Z^#, Zeng Y, Jin J, Mu W, Wei Q, Jia X, Liu J, Xie M, Luo Q, Hu G, Wang G, Zhu X, Zhou J, Xiao M, Wang J^*, Tan T^*, Huang L^*. Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. JCI Insight. 2025 May 22;10(10):e178572.

(2) Cheng Y^#, Zhang J^#, Mu W^#, Ye S, Cheng J, Zhu L, Wang G, Cao Y, Li D, Hu G^*, Huang L^*, Wang J^*, Zhou J. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther. 2025 Apr 2;33(4):1535-1551.

(3) Li Z^#*, Zhao L^#, Zhang Y, Zhu L, Mu W, Ge T, Jin J, Tan J, Cheng J, Wang J, Wang N, Zhou X, Chen L, Chang Z, Liu C, Bian Z, Liu B^*, Ye L^*, Lan Y^*, Huang L^*, Zhou J. Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients. Cell Rep. 2023 Oct 31;42(10):113263.

(4) Li H^#, Yang X, Wang Z, She W, Liu Y^*, Huang L^*, Jiang P^*. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming. ACS Nano. 2023 Jun 27;17(12):11749-11763.

(5) Tang Y^#, Xu Q^#, Luo H^#, Yan X, Wang G, Hu L, Jin J, Witte DP, Marsh RA, Huang L^*, Huang G^*, Zhou J^*. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. J Allergy Clin Immunol. 2022 Nov;150(5):1154-1167.

(6) Wei J^#, Xiao M^#, Mao Z^#, Wang N, Cao Y, Xiao Y, Meng F, Sun W, Wang Y, Yang X, Chen L, Zhang Y, Zhu H, Zhang S, Zhang T, Zhou J^*, Huang L^*. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022 Apr 11;7(1):101.

(7) Cao W^#, Wei J^#, Wang N, Xu H, Xiao M, Huang L, Cao Y, Li C, Xiao Y, Gu C, Zhang S, Li D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy. Blood. 2020 Jul 23;136(4):516-519.

(8) Wang N^#, Hu X^#, Cao W, Li C, Xiao Y, Cao Y, Gu C, Zhang S, Chen L, Cheng J, Wang G, Zhou X, Zheng M, Mao X, Jiang L, Wang D, Wang Q, Lou Y, Cai H, Yan D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Efficacy and Safety of CAR19/22 T-cell Cocktail Therapy in Patients with Refractory/Relapsed B-Cell Malignancies. Blood. 2020 Jan 2;135(1):17-27.

(9) Huang L^#, Liu D^#, Wang N^#, Ling S^#, Tang Y^#, Wu J, Hao L, Luo H, Hu X, Sheng L, Zhu L, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou K, Cao L, Dong L, Zheng X, Sui P, He J, Mo S, Yan J, Ao Q, Qiu L, Zhou H, Liu Q, Zhang H, Li J, Jin J, Fu L, Zhao W, Chen J, Du X, Qing G, Liu H, Liu X, Huang G, Ma D, Zhou J^*, Wang QF^*. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018 Feb;28(2):172-186.

(10) Tang YT^#, Wang D^#, Luo H^#, Xiao M, Zhou HS, Liu D, Ling SP, Wang N, Hu XL, Luo Y, Mao X, Ao QL, Huang J, Zhang W, Sheng LS, Zhu LJ, Shang Z, Gao LL, Zhang PL, Zhou M, Zhou KG, Qiu LG, Liu QF, Zhang HY, Li JY, Jin J, Fu L, Zhao WL, Chen JP, Du X, Huang G, Wang QF, Zhou JF^*, Huang L^*. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017 Dec 21;7(12):660.